Travere Therapeutics stock analysis
Want to see TVTX full AI Analyst Report?
Travere Therapeutics (TVTX) Stock Price & Analysis
TVTX Stock Chart & Stats
- Day’s Range
- $46.90 - $49.35
- 52-Week Range
- $22.59 - $68.73
- Previous Close
- $48.30
- Volume
- N/A
- Average Volume (3M)
- 2.00M
- Market Cap
- $4.51B
- Enterprise Value
- $5.72B
- Total Cash (Recent Filing)
- $471.82M
- Total Debt (Recent Filing)
- $616.15M
- Price to Earnings (P/E)
- ―
- Beta
- 1.57
- Next Earnings
- Feb 25, 2027 (Est.)
- EPS Estimate
- 0.44
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Product Economics
Rapid revenue expansion combined with exceptionally high gross margins indicates strong product economics and growing commercial adoption. If FILSPARI demand continues scaling across its indications, the company can build greater operating leverage and generate substantial resources to support future pipeline investment.
FILSPARI Commercial Traction
Record quarterly sales, strong conversion to paid therapy, and high adherence across IgA nephropathy and FSGS support a durable commercial foundation. Low switching and expanding prescriber adoption suggest FILSPARI may retain patients while continuing to penetrate underdiagnosed and newly launched segments.
Cash Generation And Pipeline Funding
The recent shift to positive operating and free cash flow improves Travere’s ability to fund commercial expansion and clinical development internally. Combined with reported cash and securities, this provides meaningful resources to advance the pipeline while reducing immediate reliance on additional external financing.
Bears Say
High Leverage And Thin Equity
Sharp debt growth alongside substantial equity erosion leaves Travere with a very thin capital cushion. This high leverage can constrain strategic flexibility, increase the importance of sustained FILSPARI cash generation, and make the company more vulnerable if operating performance or pipeline execution weakens.
Persistent And Worsening Losses
Despite strong revenue and gross margins, Travere has not yet translated commercial growth into consistent operating profitability. The deterioration in TTM EBITDA and net income indicates that operating costs, launch investment, and development spending remain substantial, potentially limiting retained cash and earnings visibility.
Chief Executive Transition
A CEO change during rapid commercialization and pipeline advancement introduces execution and continuity risk over the coming quarters. The incoming leader’s transition must preserve FILSPARI momentum, manage elevated investment, and maintain development priorities while stakeholders adapt to new strategic leadership.
Travere Therapeutics News
TVTX FAQ
What was Travere Therapeutics’s price range in the past 12 months?
What is Travere Therapeutics’s market cap?
When is Travere Therapeutics’s upcoming earnings report date?
How were Travere Therapeutics’s earnings last quarter?
Is Travere Therapeutics overvalued?
Does Travere Therapeutics pay dividends?
What is Travere Therapeutics’s EPS estimate?
How many shares outstanding does Travere Therapeutics have?
What happened to Travere Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Travere Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Travere Therapeutics Stock Smart Score
Company Description
Travere Therapeutics
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Eric Dube
- Employees
- 497
- Website
- www.travere.com
- Address
- 3611 Valley Centre Drive, San Diego, CA, 92130, US
Travere Therapeutics (TVTX) Earnings & Revenues
TVTX Company Deck
TVTX Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, characterized by record FILSPARI sales, approximately 120% year-over-year product growth, strong demand and persistence across IgA nephropathy and FSGS, encouraging clinical data, and continued pipeline and patent progress. The main challenges were expected fourth-quarter inventory normalization, a slight sequential decline in IgA nephropathy demand, anticipated gross-to-net pressure, substantial licensing-related expense, and the upcoming CEO transition. Positive operating momentum and pipeline progress significantly outweighed the stated headwinds.
View all TVTX earnings summariesTVTX Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 4 | 14 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 0 | 0 | 12 |









